| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
4,977 |
4,693 |
$400K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
4,010 |
3,797 |
$204K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
1,073 |
1,058 |
$95K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
1,089 |
1,088 |
$94K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
749 |
749 |
$63K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
405 |
402 |
$36K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
886 |
874 |
$33K |
| 99051 |
|
1,151 |
1,138 |
$32K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,600 |
1,559 |
$24K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,368 |
684 |
$17K |
| 87428 |
|
402 |
395 |
$14K |
| 99188 |
|
334 |
334 |
$6K |
| 99215 |
Prolong outpt/office vis |
16 |
16 |
$2K |
| 90686 |
|
443 |
442 |
$1K |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
59 |
52 |
$1K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
20 |
20 |
$800.00 |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
22 |
22 |
$683.10 |
| 90670 |
|
406 |
405 |
$671.00 |
| 90648 |
|
729 |
725 |
$640.00 |
| 90723 |
|
567 |
563 |
$517.00 |
| 92551 |
|
770 |
770 |
$354.76 |
| 96127 |
|
615 |
613 |
$330.44 |
| 81002 |
|
87 |
86 |
$301.33 |
| 99177 |
|
424 |
424 |
$249.51 |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
492 |
491 |
$229.42 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
22 |
22 |
$220.00 |
| 90680 |
|
400 |
399 |
$210.13 |
| 96160 |
|
578 |
577 |
$194.89 |
| 90734 |
|
17 |
17 |
$192.00 |
| 90715 |
|
51 |
51 |
$144.00 |
| 90651 |
|
149 |
148 |
$132.00 |
| 90633 |
|
256 |
256 |
$132.00 |
| 99173 |
|
211 |
211 |
$78.08 |
| 85018 |
|
55 |
55 |
$37.98 |
| 96161 |
|
713 |
709 |
$0.00 |
| 90696 |
|
53 |
53 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
214 |
213 |
$0.00 |
| 90677 |
|
337 |
335 |
$0.00 |
| 90656 |
|
107 |
107 |
$0.00 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
37 |
37 |
$0.00 |
| 90619 |
|
70 |
70 |
$0.00 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
60 |
57 |
$0.00 |
| 90716 |
|
12 |
12 |
$0.00 |
| 90620 |
|
36 |
36 |
$0.00 |
| G9920 |
Screening performed and negative |
729 |
722 |
$0.00 |
| 90710 |
|
58 |
58 |
$0.00 |
| 90661 |
|
134 |
134 |
$0.00 |
| 90700 |
|
12 |
12 |
$0.00 |